Demant A/S (CPH:DEMANT)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 42.18B |
| Revenue (ttm) | 22.97B |
| Net Income (ttm) | 1.55B |
| Shares Out | 210.90M |
| EPS (ttm) | 7.31 |
| PE Ratio | 17.86 |
| Forward PE | 15.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,121 |
| Average Volume | 447,690 |
| Open | 203.20 |
| Previous Close | 203.60 |
| Day's Range | 199.70 - 203.20 |
| 52-Week Range | 175.00 - 293.00 |
| Beta | 0.74 |
| RSI | 48.32 |
| Earnings Date | Aug 11, 2026 |
About Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark. [Read more]
Financial Performance
In 2025, Demant's revenue was 22.97 billion, an increase of 2.46% compared to the previous year's 22.42 billion. Earnings were 1.55 billion, a decrease of -35.27%.
Financial StatementsNews
Reminder - Waterdrop (WDH) Goes Ex-Dividend Soon
Looking at the universe of stocks we cover at Dividend Channel, on 4/24/26, Waterdrop Inc (Symbol: WDH) will trade ex-dividend, for its semi-annual dividend of $0.03, payable on 5/20/26. As a percenta...
Demant Earnings Call Transcript: Q4 2025
Reported 2% organic growth for 2025, with strong Q4 performance in Hearing Care and Diagnostics, but margin pressure from ASP and mix. 2026 guidance targets 3%-6% organic growth, DKK 4.1-4.5bn EBIT, and cost savings, with Zeal rollout and KIND acquisition as key drivers.
Demant Earnings Call Transcript: Q3 2025
Q3 results landed at the low end of expectations, with 3% organic growth and margin pressure from negative ASP and mix effects. Market share gains were achieved in hearing aids, and the Oticon Seal launch drew strong interest. 2025 guidance remains, but at the lower end of the range.
Demant Earnings Call Transcript: Q2 2025
Flat organic growth and margin contraction in H1 2025 were driven by weak market conditions, unfavorable mix, and FX headwinds. EBIT guidance and market growth expectations were revised down, while strong cash flow and the KIND Group acquisition marked key developments.
Demant Transcript: M&A Announcement
The acquisition of Kind Group for EUR 700 million expands the company's presence in Germany, creating one of the largest retail footprints in the market. Synergies are expected to drive profitability, with full benefits realized by 2028, and the deal is projected to be earnings accretive from year one.
Demant Transcript: M&A Announcement (Media)
A €700 million acquisition of a leading German hearing care retailer will expand the buyer's global clinic network, strengthen its market position, and is expected to add €300 million in revenue by 2026. Integration will be gradual, with no immediate layoffs planned.
Demant Earnings Call Transcript: Q1 2025
Q1 2025 saw flat organic growth and a decline in hearing aid sales due to U.S. market weakness and currency headwinds, prompting a downward revision of full-year guidance. Hearing care outperformed the market, while diagnostics remained flat. EBIT guidance was lowered by DKK 400 million.
Demant Earnings Call Transcript: Q4 2024
Revenue grew 4% in 2024, driven by hearing care and acquisitions, while EBIT declined 2% due to FX and lower leverage. 2025 guidance targets 3%-7% organic growth and DKK 4.5-4.9 billion EBIT, with continued focus on core hearing healthcare and strong cash flow.
Demant Earnings Call Transcript: Q3 2024
Q3 delivered strong hearing care growth and stable gross margin, but hearing aids and diagnostics faced headwinds from competition and weak markets, especially in China. Full-year guidance is unchanged, with management expecting a stronger Q4 and continued focus on cost control.
Demant Earnings Call Transcript: Q2 2024
Organic growth and EBIT fell short of expectations due to U.S. managed care losses and subdued diagnostics, but strong gross margin and cash flow were supported by higher ASP and product mix. EPOS restructuring and divestments are underway, with a revised outlook for modest growth and profitability.